Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- Roxadustat is still expected to be first HIF-PHI to launch in the EU & US markets, which may contribute to its superior uptake vs. other HIF-PHI candidates, given the current lack of clinical differentiation between candidates of this class
- In addition to progressing vadadustat’s Phase III trials in Japan, Mitsubishi Tanabe also appears focused on understanding the impact of a commonly used renal anemia strategy, iron supplementation, on the pharmacokinetics of vadadustat
- Daprodustat’s Phase III data appears to strengthen the asset’s long-term safety and efficacy profile, with daprodustat on track to become the second or third HIF-PHI approved in Japan for DD-CKD.

Scope

- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Companies Mentioned
3SBio
Aevi Genomic Medicine
Akebia Therapeutics
Allergan
AMAG Pharma
Amgen
Astellas
AstraZeneca
Bayer
Biocad
Chong Kun Dang Pharmaceutical
Chugai
CJ HealthCare
Dong-A
Dr Reddy’s
FibroGen
Fida
Genexine
GSK
Hospira
Janssen
Japan Tobacco
JCR Pharma
Jiangsu Hansoh Pharmaceutical
Keryx
Kissei
Kyowa Hakko Kirin
Luitpold
Medice
Mitsubishi Tanabe Pharma
Novartis
Orion
Otsuka
Pfizer
Pharmacosmos
Pieris Pharmaceuticals
Prolong Pharmaceuticals
Reliance Life Sciences
Roche
Rockwell
Sandoz
Sanofi Aventis
Sanwa Kagaku Kenkyusho
Serum Institute of India
Shenyang Sunshine Pharmaceutical
Shield Therapeutics
Sidero Biosciences
Stada
SynBio
Taisho Pharmaceuticals
Teva
Torii
United Biomedical
Vifor
Xenetic Biosciences
Zeria Pharma
Zydus Cadila